Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question |
| |
Authors: | van Kuilenburg André B P |
| |
Affiliation: | a Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands |
| |
Abstract: | The treatment of cancer patients with 5-fluorouracil (5FU)-based chemotherapy can be accompanied by severe and sometimes lethal toxicity. Dihydropyrimidine dehydrogenase (DPD) plays a pivotal role in the metabolism of 5FU and as such, a deficiency of DPD has been recognized as an important risk factor, predisposing patients to the development of severe 5FU-associated toxicity. To date, screening of patients for the presence of a DPD deficiency prior to the treatment is not yet routinely performed. Taking into account the relatively small impact of adjuvant 5FU-based chemotherapy on survival, patients should be informed about the risks of the therapy and should be offered the possibility of testing for the presence of a DPD deficiency in advance of receiving such treatment. |
| |
Keywords: | Dihydropyrimidine dehydrogenase 5-Fluorouracil Pharmacogenetics DPYD Toxicity |
本文献已被 InformaWorld PubMed 等数据库收录! |
|